Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease

American Journal of the Medical Sciences

Volumn 332, Issue 3, 2006, Pages 156-158

  Diskin, Charles J ^a   Stokes, Thomas J ^a   Dansby, Linda M ^a   Radcliff, Lautrec ^a   Carter, Thomas B ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Drug clearance; Hemodialysis; Methotrexate; Peritoneal dialysis

Indexed keywords

CEFTAZIDIME; DOPAMINE; FLUCONAZOLE; FOLINIC ACID; METHOTREXATE; PHENYLEPHRINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN;

ADULT; ANAMNESIS; ANOREXIA; ARTICLE; CASE REPORT; CREATININE CLEARANCE; DIALYSATE LEVEL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; GENERAL CONDITION DETERIORATION; HEMATEMESIS; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; LABORATORY TEST; MALE; NAUSEA; ODYNOPHAGIA; PANCYTOPENIA; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ARTHRITIS, RHEUMATOID; FATAL OUTCOME; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METHOTREXATE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS;

EID: 33748752303     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200609000-00013     Document Type: Article

References (9)

1. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
2. Boulanger H, Launay-Vacher V, Hierniaux P, et al. Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis. Nephrol Dial Transplant 2001;16:1087.
3. Rochas MA, Tufenkji AE, Levillain P, et al. Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis. Arzneimittelforschung 1991;41:1286-8.
4. Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of PD. Arch Intern Med 1978;138:1146-7.
5. Heaf JG, Sarac S, Afzal S. A high peritoneal large pore fluid flux causes hypoalbuminaemia and is a risk factor for death in PD patients. Nephrol Dial Transplant 2005;20:2194-201.
6. Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of methotrexate using high-flux HD membranes. Am J Kidney Dis 1996;28:846-54.
7. Thomson AH, Daly M, Knepil J, et al. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. Cancer Chemother Pharmacol 1996;38:566-70.
8. Gauthier E, Gimonet JF, Piedbois P, et al. Effectiveness of HD in a case of acute methotrexate poisoning. Presse Med 1990;19:2023-5.
9. Widemann BC, Balis FM, Kempf-Bielack B, et al.. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222-32.